Moderna shares rose 5.4% this afternoon to a price of $140.02. The stock is still trading within range of its average target price of $137.59, and over the last 52 weeks, it has recorded a 4.9% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $60.0 to $310.0 dollars per share, with an average rating of buy.
Moderna has an average level of shares sold short, at 7.2% of its total share float. The stock's short ratio (also called days to cover) is 6.93. The company's insiders own 9.59% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 73.1% of Moderna's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Baillie Gifford and Company | 12% | 44,655,817 | $6,252,707,687 |
| 2024-03-31 | Vanguard Group Inc | 10% | 39,036,872 | $5,465,942,984 |
| 2024-03-31 | Blackrock Inc. | 7% | 25,395,878 | $3,555,930,946 |
| 2024-03-31 | State Street Corporation | 4% | 14,452,035 | $2,023,574,002 |
| 2024-03-31 | FMR, LLC | 4% | 13,599,837 | $1,904,249,234 |
| 2024-03-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $1,353,438,682 |
| 2024-03-31 | Theleme Partners LLP | 2% | 7,321,797 | $1,025,198,047 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 6,750,479 | $945,202,098 |
| 2024-03-31 | Wellington Management Group, LLP | 1% | 5,604,703 | $784,770,538 |
| 2024-03-31 | Morgan Stanley | 1% | 5,493,965 | $769,265,002 |
